(AOF) – Pharnext announces a fundraising of 250,000 euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. This biotech (developing new therapies for neurodegenerative diseases without satisfactory therapeutic solution) specifies that this operation could give rise to the creation of 265,957 new shares on the basis of the last listed price and that the participation of a shareholder holding 1% of the capital prior to this new drawing would be 0.92%.
In addition, Pharnext simultaneously announces a “loss-driven” capital reduction by reducing the par value of the company’s shares.
The par value of the share is reduced from 1.00 euros to 0.20 euros. The company’s share capital, divided into 311,727 shares, was reduced from 311,727 euros to 62,345.40 euros.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.